Actively Recruiting
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Led by Shanghai Chest Hospital · Updated on 2026-01-22
100
Participants Needed
2
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.
CONDITIONS
Official Title
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed metastatic esophageal squamous cell carcinoma (stage IVB, M1) by pathology
- ECOG performance status of 0 or 1
- No prior anti-tumor treatment
- Adequate blood, kidney, liver, and heart function suitable for chemotherapy and immunotherapy as evaluated by investigators
You will not qualify if you...
- Esophageal cancer that is not squamous cell carcinoma or mixed with other types
- Patients considered potentially curable by surgery
- Presence of pleural metastasis, malignant pleural effusion, or pericardial effusion
- Any previous anti-tumor therapy for esophageal cancer including surgery, radiotherapy, chemotherapy, or immunotherapy
- High risk of gastrointestinal bleeding, esophageal fistula, or perforation
- Patient-Generated Subjective Global Assessment (PG-SGA) score of 9 or higher
- Unstable heart disease or symptoms
- History of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, or uncontrolled acute lung disease
- Active or history of autoimmune disease
- Immunodeficiency or active infection requiring systemic treatment
- Pregnant or breastfeeding
- Having a second primary cancer or cancer history within the past 5 years (except fully cured cervical carcinoma in situ or certain skin carcinomas)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Shanghai Ruijin Hospital
Shanghai, China, 200020
Actively Recruiting
2
Shanghai Chest Hospital
Shanghai, China, 200030
Actively Recruiting
Research Team
W
Wen Yu, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here